Sartorius Stedim Biotech S.A. (SDMHF)
USD 201.5
(0.0%)
USD 201.5
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 309.7 Million EUR | -64.65% |
| 2022 | 876.1 Million EUR | 111.41% |
| 2021 | 414.4 Million EUR | 23.36% |
| 2020 | 335.93 Million EUR | 43.25% |
| 2019 | 234.5 Million EUR | 12.71% |
| 2018 | 208.05 Million EUR | 29.15% |
| 2017 | 161.08 Million EUR | 4.82% |
| 2016 | 153.67 Million EUR | 30.24% |
| 2015 | 117.99 Million EUR | 62.89% |
| 2014 | 72.44 Million EUR | 9.3% |
| 2013 | 66.27 Million EUR | 16.77% |
| 2012 | 56.75 Million EUR | 31.83% |
| 2011 | 43.05 Million EUR | 11.79% |
| 2010 | 38.51 Million EUR | 32.38% |
| 2009 | 29.09 Million EUR | 122.23% |
| 2008 | 13.09 Million EUR | 176.06% |
| 2007 | 4.74 Million EUR | -83.66% |
| 2006 | 29.01 Million EUR | 31.24% |
| 2005 | 22.11 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 47.6 Million EUR | -15.0% |
| 2024 Q1 | 56 Million EUR | 40.7% |
| 2024 Q3 | 25.5 Million EUR | -46.43% |
| 2023 Q4 | 39.8 Million EUR | 54.86% |
| 2023 Q3 | 25.7 Million EUR | -80.69% |
| 2023 Q2 | 133.1 Million EUR | 19.8% |
| 2023 Q1 | 111.1 Million EUR | -40.49% |
| 2023 FY | 309.7 Million EUR | -64.65% |
| 2022 FY | 876.1 Million EUR | 111.41% |
| 2022 Q4 | 186.7 Million EUR | -6.93% |
| 2022 Q1 | 270.2 Million EUR | 3189.91% |
| 2022 Q3 | 200.6 Million EUR | -6.61% |
| 2022 Q2 | 214.8 Million EUR | -20.5% |
| 2021 Q1 | 125.8 Million EUR | 10.11% |
| 2021 Q2 | 148.5 Million EUR | 18.04% |
| 2021 Q3 | 148.8 Million EUR | 0.2% |
| 2021 Q4 | 8.21 Million EUR | -94.48% |
| 2021 FY | 414.4 Million EUR | 23.36% |
| 2020 Q4 | 114.24 Million EUR | 14.48% |
| 2020 Q3 | 99.8 Million EUR | 50.3% |
| 2020 Q2 | 66.4 Million EUR | -11.11% |
| 2020 Q1 | 74.7 Million EUR | 35.64% |
| 2020 FY | 335.93 Million EUR | 43.25% |
| 2019 Q3 | 58.5 Million EUR | -9.72% |
| 2019 Q4 | 55.07 Million EUR | -5.86% |
| 2019 FY | 234.5 Million EUR | 12.71% |
| 2019 Q2 | 64.8 Million EUR | 15.51% |
| 2019 Q1 | 56.1 Million EUR | -17.08% |
| 2018 Q2 | 50.1 Million EUR | 22.49% |
| 2018 Q1 | 40.9 Million EUR | -8.88% |
| 2018 FY | 208.05 Million EUR | 29.15% |
| 2018 Q4 | 67.65 Million EUR | 36.95% |
| 2018 Q3 | 49.4 Million EUR | -1.4% |
| 2017 Q2 | 39.1 Million EUR | -1.76% |
| 2017 FY | 161.08 Million EUR | 4.82% |
| 2017 Q4 | 44.88 Million EUR | 20.34% |
| 2017 Q3 | 37.3 Million EUR | -4.6% |
| 2017 Q1 | 39.8 Million EUR | 16.11% |
| 2016 Q1 | 36.4 Million EUR | 45.61% |
| 2016 Q4 | 34.27 Million EUR | -21.56% |
| 2016 FY | 153.67 Million EUR | 30.24% |
| 2016 Q3 | 43.7 Million EUR | 11.2% |
| 2016 Q2 | 39.3 Million EUR | 7.97% |
| 2015 Q4 | 24.99 Million EUR | -39.76% |
| 2015 Q1 | 18.7 Million EUR | 1.4% |
| 2015 Q2 | 32.7 Million EUR | 74.87% |
| 2015 FY | 117.99 Million EUR | 62.89% |
| 2015 Q3 | 41.5 Million EUR | 26.91% |
| 2014 Q4 | 18.44 Million EUR | -6.39% |
| 2014 Q2 | 19.5 Million EUR | 25.0% |
| 2014 Q3 | 19.7 Million EUR | 1.03% |
| 2014 FY | 72.44 Million EUR | 9.3% |
| 2014 Q1 | 15.6 Million EUR | -9.18% |
| 2013 Q2 | 20.6 Million EUR | 0.0% |
| 2013 Q4 | 17.17 Million EUR | 16.05% |
| 2013 Q3 | 14.8 Million EUR | -28.16% |
| 2013 FY | 66.27 Million EUR | 16.77% |
| 2012 FY | 56.75 Million EUR | 31.83% |
| 2012 Q2 | 12 Million EUR | 0.0% |
| 2011 Q2 | 9.5 Million EUR | 0.0% |
| 2011 FY | 43.05 Million EUR | 11.79% |
| 2010 FY | 38.51 Million EUR | 32.38% |
| 2010 Q2 | 9 Million EUR | 0.0% |
| 2009 FY | 29.09 Million EUR | 122.23% |
| 2008 FY | 13.09 Million EUR | 176.06% |
| 2007 FY | 4.74 Million EUR | -83.66% |
| 2006 FY | 29.01 Million EUR | 31.24% |
| 2005 FY | 22.11 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| American Medical Technologies Inc. | -926.89 Thousand USD | 33512.702% |
| Ansell Limited | 76.5 Million USD | -304.837% |
| Ansell Limited | 76.5 Million USD | -304.837% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 24.28 Million USD | -1175.525% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | -1.63 Million USD | 19097.168% |
| Psykey, Inc. | -1.32 Million USD | 23492.104% |
| ConvaTec Group Plc | 130.3 Million USD | -137.682% |
| ConvaTec Group Plc | 130.3 Million USD | -137.682% |
| Encision Inc. | -691.78 Thousand USD | 44868.374% |
| Golden Valley Development, Inc | -141.81 Thousand USD | 218489.265% |
| Hear AtLast Holdings, Inc. | -234.36 Thousand USD | 132243.741% |
| Innovative MedTech Inc. | -7.93 Million USD | 4001.046% |
| LifePoint, Inc. | -15.23 Million USD | 2133.273% |
| Medite Cancer Diagnostics, Inc. | -6.81 Million USD | 4647.056% |
| Paradigm Medical Industries, Inc. | -474 Thousand USD | 65437.553% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | -274.44 Thousand USD | 112945.514% |
| Reflect Scientific, Inc. | -459.02 Thousand USD | 67568.651% |
| SmileDirectClub, Inc. | -86.4 Million USD | 458.432% |
| Sector 10, Inc. | 7036.00 USD | -4401548.664% |
| Shandong Weigao Group Medical Polymer Company Limited | 2 Billion USD | 84.53% |
| SheerVision, Inc. | -71.37 Thousand USD | 433999.35% |
| United Health Products, Inc. | -2.62 Million USD | 11905.889% |
| Vasamed, Inc. | -4.88 Million USD | 6435.726% |
| Wearable Health Solutions, Inc. | -2.38 Million USD | 13066.476% |
| Yubo International Biotech Limited | -1.2 Million USD | 25806.258% |